Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=22c6625e-55ff-47d3-9b6f-3c65b01211b6&Preview=1
Date 12/17/2012
Company Name Naurex
Mailing Address 1801 Maple Ave. Evanston, IL 60201
Company Description Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR).
Proceeds Purposes Naurex will use the proceeds from the Series B financing to fund a number of key programs from its NMDA receptor modulator platform, including conducting a Phase Ilb trial of GLYX-13, the company’s lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and further developing its second- and third-generation programs for other CNS disorders.